2157.HK
Lepu touts itself as the only biotech company in China working on all three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development.

The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for a sale price of HK$4.58 per share.

Looking Up: The company expects to receive approximately 230 million yuan ($32 million) in net proceeds from the placement, which it will use for R&D, clinical trials and other workstreams for its antibody-drug conjugates (ADC) and oncolytic virus (OV) products, and to replenish its working capital.

Take Note: The placement share price represents a 13.09% discount to the company’s closing price of HK$5.28 on Thursday.

Digging Deeper: Lepu touts itself as the only biotech company in China working on three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development. The company made a Hong Kong IPO in 2022 just as medical stocks were falling out of favor, making it settle for a valuation that was 14% below what it got in its post-series-C funding, raising about HK$800 million ($103 million). It recorded 225 million yuan in revenue last year but failed to earn a profit after recording its first sales at the end of 2022.

Market Reaction: Lepu’s shares fell on Friday and were down 6.3% to HK$4.94 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by A. Au

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Ele.me get rolled into Alibaba's e-commerce

Alibaba turns up its ‘instant retail’ game

The merger of its Ele.me service with its core e-commerce business marks a new stage in the e-commerce giant’s three-way “on-demand retail wars” with Meituan and JD.com Key Takeaways: Alibaba…
Chow Tai Fook issues first convertible bonds in 14 years: What does it see for the future?

Chow Tai Fook rediscovers gold in convertible bonds

The fundraising, even as the Hong Kong jeweler has sufficient financial resources to run its current operation, could hint at plans for its next growth phase Key Takeaways: Chow Tai…